Michael Gelband’s GT Biopharma GTBP Stock Holding History

Michael Gelband’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-740	Closed	-$150K	–	2337
2021 Q3	$150K	Buy	+740	New	+$223K	﹤0.01%	1838

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Michael Gelband's GTBP Position: Q4 2021 in Review

Michael Gelband sold out of GT Biopharma (GTBP) in Q4 2021, closing a stake of 740 shares — an estimated $150K sold.

Michael Gelband first reported a position in GTBP in Q3 2021 and held it in 1 quarter. The position peaked at $150K in Q3 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q4 2021.

Michael Gelband reported no remaining GT Biopharma position as of Q4 2021 after selling out during the quarter.
Michael Gelband sold 740 GT Biopharma shares in Q4 2021, an estimated $150K.
Michael Gelband first reported a position in GT Biopharma in Q3 2021 and held it in 1 quarter.
Michael Gelband's GT Biopharma position peaked at $150K in Q3 2021.
53 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.